ALN-VSP: Interim Phase I data

Interim data from tumor biopsies from 8 patients in an open-label, dose-escalation Phase I trial showed that 0.4-1.25 mg/kg IV ALN-VSP produced ALN-VSP concentrations of 0.3-142 ng/g tissue, which Alnylam said was "pharmacologically relevant." Additionally, 2 of 3 patients who received the 0.4 mg/kg dose showed evidence of RNAi-mediated VEGF mRNA cleavage. ...